The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart

被引:22
作者
Chan, Kevin [1 ]
Moe, Sharon M. [2 ]
Saran, Rajiv [3 ]
Libby, Peter [4 ]
机构
[1] NIDDK, Div Kidney Urol & Hematol, 6707 Democracy Blvd, Bethesda, MD 20892 USA
[2] Indiana Univ Sch Med, Div Nephrol, 950 W Walnut St R2-202, Indianapolis, IN 46202 USA
[3] Univ Michigan, Dept Internal Med, Div Nephrol, 1500 E Med Ctr Dr 31, Ann Arbor, MI 48109 USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 77 Ave Louis Pasteur,NRB 741-G, Boston, MA 02115 USA
关键词
End-stage renal disease; Sudden death; Haemodialysis initiation; CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY-DISEASE; SENSITIVITY CARDIAC TROPONIN; 3RD UNIVERSAL DEFINITION; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; RISK STRATIFICATION; DIABETES-MELLITUS;
D O I
10.1093/eurheartj/ehaa1049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) patients require dialysis to manage the progressive complications of uraemia. Yet, many physicians and patients do not recognize that dialysis initiation, although often necessary, subjects patients to substantial risk for cardiovascular (CV) death. While most recognize CV mortality risk approximately doubles with CKD the new data presented here show that this risk spikes to >20 times higher than the US population average at the initiation of chronic renal replacement therapy, and this elevated CV risk continues through the first 4 months of dialysis. Moreover, this peak reflects how dialysis itself changes the pathophysiology of CV disease and transforms its presentation, progression, and prognosis. This article reviews how dialysis initiation modifies the interpretation of circulating biomarkers, alters the accuracy of CV imaging, and worsens prognosis. We advocate a multidisciplinary approach and outline the issues practitioners should consider to optimize CV care for this unique and vulnerable population during a perilous passage.
引用
收藏
页码:1244 / +
页数:14
相关论文
共 153 条
[1]   Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial [J].
Agarwal, Rajiv ;
Sinha, Arjun D. ;
Pappas, Maria K. ;
Abraham, Terri N. ;
Tegegne, Getachew G. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (03) :672-681
[2]   Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP) A Randomized, Controlled Trial [J].
Agarwal, Rajiv ;
Alborzi, Pooneh ;
Satyan, Sangeetha ;
Light, Robert P. .
HYPERTENSION, 2009, 53 (03) :500-U23
[3]  
Ahmad OB, 2000, GPE DISCUSSION PAPER, V31, P1
[4]   Home blood pressures are of greater prognostic value than hemodialysis unit recordings [J].
Alborzi, Pooneh ;
Patel, Nina ;
Agarwal, Rajiv .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (06) :1228-1234
[5]   Coronary artery calcification in CKD-5D patients is tied to adverse cardiac function and increased mortality [J].
Anaya, Paul ;
Blomquist, Gustav A. ;
Davenport, Daniel L. ;
Monier-Faugere, Marie-Claude ;
Sorrell, Vincent L. ;
Malluche, Hartmut H. .
CLINICAL NEPHROLOGY, 2016, 86 (06) :291-302
[6]  
[Anonymous], The odds of dying from
[7]  
[Anonymous], 2014, ELIQUIS APIXABAN TAB
[8]  
[Anonymous], 2018, 2018 USRDS ANN DATA
[9]   High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial [J].
Aoun, Mabel ;
Makki, Maha ;
Azar, Hiba ;
Matta, Hiam ;
Chelala, Dania Nehme .
BMC NEPHROLOGY, 2017, 18
[10]   Study of Heart and Renal Protection (SHARP) [J].
Baigent, C ;
Landry, M .
KIDNEY INTERNATIONAL, 2003, 63 :S207-S210